Physician profile
Brian Dearing
NPI 1164478178
$964.14
in general payments reported to CMS, 2019-2025
13 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $53.69 · 2021: $165 · 2022: $63.34 · 2023: $73.21 · 2024: $105 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $302.51 | 2019-2025 | Navitor, Ensite |
| Boston Scientific Corporation | $229.71 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Accolade Sr |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Philips North America LLC | $107.27 | 2025 | Zenition 90 M |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.47 | 2022-2023 | Lifevest |
| Penumbra, INC. | $32.89 | 2022 | |
| Abiomed | $27.43 | 2019 | |
| Amgen INC. | $18.96 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $15.61 | 2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $15.05 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.96 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.46 | 2024 | Arcalyst |
| Pfizer INC. | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dearing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.